newsfilter
← Latest News
GlobeNewswire·

LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update

Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Expects to Complete